...developer Biosite Diagnostics; Coulter Pharmaceutical, a developer of lymphoma therapies; and Epix Medical Inc. (formerly Metasyn...

...a contrast imaging agent designed for use with magnetic resonance imaging to diagnose cardiovascular disease. Metasyn Inc....

...Cambridge, Mass. Product: MS-325 injectable contrast agent for MRI Indication: Image blood vessels Status: Metasyn's...

...develop and market MS-325 , Metasyn's agent for imaging cardiovascular systems in magnetic resonance imaging. Metasyn...
...The companies will share development costs. Mallinckrodt is responsible for product marketing worldwide, excluding Japan. Metasyn Inc....

...nature of magnetic resonance imaging and ultrasound imaging make them highly appealing as diagnostic modalities. Metasyn Inc....
...in the past few years, driven by improvements in both software and hardware, according to Metasyn...
...what used to be a multimillion-dollar investment is now in the range of $750,000-$1 million. Metasyn's...

...Kogyo will buy an additional $2.5 million of shares at the offering price. PRIVATE ROUNDS: Metasyn Inc....
...the company determine when to pursue an IPO, according to President and CEO Michael Webb. Metasyn...

...METASYN said Massachusetts General Hospital received notices of allowance for patents in Europe and Japan. METASYN...
...complexes to enhance the blood and/or liver on MRI scans and increase their signal-generating efficiency. METASYN...
...used in conjunction with MRI to produce images of blood vessels throughout the cardiovascular system. METASYN Inc....

...The companies entered into an agreement in Japan for MS-325 , METASYN's vascular enhancement agent for...
...enhancement agent for magnetic resonance imaging. Daiichi is responsible for clinical development, registration and commercialization. METASYN...
...METASYN retains rights to MS-325 outside of Japan, and will manufacture the product for Daiichi. METASYN Inc....

...MRI agent with increased sensitivity and the potential to distinguish benign tumors from malignant tumors. Metasyn...
...agents, MS-136, led to significant signal enhancement in a rat model of malignant breast tumors. Metasyn Inc....